You are here

Article Text

Article menu
Download PDFPDF
Ovarian Cancer
Ovarian Cancer: Sites of Recurrence
  1. Pascale Amate, MD*,
  2. Cyrille Huchon, MD, PhD†,#,
  3. Anne Lucie Dessapt, MD*,
  4. Chérazade Bensaid, MD*,
  5. Jacques Medioni, MD, PhD‡,§,
  6. Marie-Aude Le Frère Belda, MD, PhD‡∥,
  7. Anne-Sophie Bats, MD, PhD*,‡, and
  8. Fabrice R. Lécuru, MD, PhD*,‡,
  1. *Service de Chirurgie Cancérologique Gynécologique et du Sein, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, Paris, France;
  2. †Service de Gynécologie & Obstétrique, CHI Poissy-St-Germain, Poissy, France;
  3. ‡Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, France;
  4. §Service d’Oncologie Médicale, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, Paris, France;
  5. ∥Service d’Anatamopathologie, Hôpital Européen Georges Pompidou, Assistance Publique Hôpitaux de Paris, Paris, France;
  6. INSERM UMR-S 747, Université Paris Descartes, Sorbonne Paris Cité, Paris, France; and
  7. #Equipe d’accueil EA 7285 “Risques, cliniques et sécurité en santé des femmes et en santé périnatale,” Université Versailles-Saint-Quentin en Yvelines, Versailles, France.
  1. Address correspondence and reprint requests to Fabrice R. Lécuru, MD, PhD, Service de Chirurgie Cancérologique Gynécologique et du Sein, Hôpital Européen Georges Pompidou, 20 Rue Leblanc, 75015, Paris, France. E-mail: fabrice.lecuru{at}egp.aphp.fr.

Abstract

Introduction Improved knowledge of recurrence sites after contemporary surgical management of ovarian cancer is needed.

Material and Methods We retrospectively reviewed consecutive patients managed for epithelial ovarian or tubal cancer with surgery and platinum-based chemotherapy between January 1, 2005, and December 31, 2009, in a tertiary teaching hospital. The site of first recurrence was recorded. Univariate analysis was performed to identify factors associated with site-specific recurrence. Overall survival and progression-free survival were computed using the Kaplan-Meier method, and log-rank tests were performed to assess the impact on survival of the variables of interest.

Results Recurrences were noted in 3 (20%) of 15 International Federation of Gynecologists and Obstetricians stage I to IIa patients and 36 (62.1%) of 58 International Federation of Gynecologists and Obstetricians IIb to IV patients, and the median progression-free survival was 21.6 (2.5–71) and 19.3 (1.8–67.6) months, respectively. In the advanced-disease group, 75% of recurrences involved the peritoneum and 40% were confined to the peritoneum; peritoneal recurrences developed at both treated and untreated sites. Peritoneal recurrence was associated with greater initial peritoneal involvement (Sugarbaker score, 12.1 ± 8.2 vs 7.1 ± 7.4; P = 0.01) and residual postoperative tumor. Nodal recurrences were noted in 38% of all recurrences, usually in combination with peritoneal recurrence and in the abdominal territories. Isolated distant metastasis was a rare mode of recurrence (8%).

Conclusions The peritoneum is the main recurrence site in both early and advanced ovarian cancer. Initial disease spread and extent of surgery are associated with the recurrence risk. This article supports the view that more attention should be directed toward extensive treatment of the peritoneum.

  • Ovarian cancer
  • Recurrence

https://doi.org/10.1097/IGC.0000000000000007

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • The authors declare no conflicts of interest.